Sight Sciences, Inc. (SGHT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 28 | 49 | 71 | 81 | 80 | 77 | 83 | 90 |
| Operating profit | $m | -37 | -28 | ||||||
| Net profit | $m | -35 | -63 | -86 | -56 | -52 | -38 | -30 | -34 |
| EPS reported | $ | -0.74 | -0.56 | ||||||
| Operating cashflow per share | $ | -0.57 | -0.43 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.57 | -0.43 | ||||||
| Free cash flow | $m | -30 | -23 | ||||||
| Net debt | $m | -52 | -38 | ||||||
| Book value equity | $m | 64 | 53 | ||||||
| Book value per share | $ | 1.23 | 0.97 | ||||||
| Number of shares | m | 52.15 | 54.51 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 6.47 | 7.82 | ||||||
| P/S LTM | x | 5.35 | 4.96 | ||||||
| P/FCF LTM | x | -13.82 | -17.72 | ||||||
| EV/EBITDA LTM | x | -11.05 | -14.07 | ||||||
| EV/Sales LTM | x | 4.68 | 4.86 | ||||||
| Earnings Yield LTM | % | -9.29% | -6.71% | ||||||
| FCF Yield | % | -7.23% | -5.64% | ||||||
| Quality | |||||||||
| ROE | % | -60.10% | -50.64% | ||||||
| ROIC | % | -35.42% | -29.34% | ||||||
| Operating margin | % | -47.95% | -33.43% | ||||||
| Gross margin | % | +86.17% | +87.96% | ||||||
| FCF/Sales | % | -38.67% | -27.98% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -3.13% | +4.40% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.73 | -0.56 | ||||||
| Net Debt/EBITDA | x | 1.56 | 1.47 | ||||||
| EBIT/Net interest | x | -7.21 | -10.65 | ||||||
| Net debt/market cap | % | +9.75% | +9.21% | ||||||
| Net debt/Equity | x | -0.81 | -0.71 | ||||||
| Gross debt/equity | x | 0.64 | 0.79 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free